The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Pharmacodynamic Evaluation of the Intracellular Activities of Antibiotics against Staphylococcus aureus in a Model of THP-1 Macrophages
Open accessAbstract
The pharmacodynamic properties governing the activities of antibiotics against intracellular Staphylococcus aureus are still largely undetermined. Sixteen antibiotics of seven different pharmacological classes (azithromycin and telithromycin [macrolides]; gentamicin [an aminoglycoside]; linezolid [an oxazolidinone]; penicillin V, nafcillin, ampicillin, and oxacillin [β-lactams]; teicoplanin, vancomycin, and oritavancin [glycopeptides]; rifampin [an ansamycin]; and ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin [quinolones]) have been examined for their activities against S. aureus (ATCC 25923) in human THP-1 macrophages (intracellular) versus that in culture medium (extracellular) by using a 0- to 24-h exposure time and a wide range of extracellular concentrations (including the range of the MIC to the maximum concentration in serum [ C max ; total drug] of humans). All molecules except the macrolides caused a net reduction in bacterial counts that was time and concentration/MIC ratio dependent (four molecules tested in detail [gentamicin, oxacillin, moxifloxacin, and oritavancin] showed typical sigmoidal dose-response curves at 24 h). Maximal intracellular activities remained consistently lower than extracellular activities, irrespective of the level of drug accumulation and of the pharmacological class. Relative potencies (50% effective concentration or at a fixed extracellular concentration/MIC ratio) were also decreased, but to different extents. At an extracellular concentration corresponding to their C max s (total drug) in humans, only oxacillin, levofloxacin, garenoxacin, moxifloxacin, and oritavancin had truly intracellular bactericidal effects (2-log decrease or more, as defined by the Clinical and Laboratory Standards Institute guidelines). The intracellular activities of antibiotics against S. aureus (i) are critically dependent upon their extracellular concentrations and the duration of cell exposure (within the 0- to 24-h time frame) to antibiotics and (ii) are always lower than those that can be observed extracellularly. This model may help in rationalizing the choice of antibiotic for the treatment of S. aureus intracellular infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Ohkuma, S., & Poole, B. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.7.3327 · Cited by 2,174
Auwerx, J. (1991) · Experientia · doi:10.1007/bf02041244 · Cited by 814
The pharmacokinetics of azithromycin in human serum and tissues
Foulds, G., Shepard, R. M., & Johnson, R. B. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.suppl_a.73 · Cited by 755
Craig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
The Clinical Pharmacokinetics of Levofloxacin
Fish, D. N., & Chow, A. T. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732020-00002 · Cited by 475
Staphylococcal Cell Wall: Morphogenesis and Fatal Variations in the Presence of Penicillin
Giesbrecht, P., Kersten, T., Maidhof, H., & Wecke, J. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.4.1371-1414.1998 · Cited by 304
Killing and regrowth of bacteria in vitro: a review.
Craig, W. A., & Ebert, S. C. (1990) · PubMed · Cited by 303
Mechanism of action of oritavancin and related glycopeptide antibiotics
Allen, N. (2003) · FEMS Microbiology Reviews · doi:10.1016/s0168-6445(02)00144-4 · Cited by 276
Glycopeptide Antibiotics: from Conventional Molecules to New Derivatives
Van Bambeke, F., Van Laethem, Y., Courvalin, P., & Tulkens, P. M. (2004) · Drugs · doi:10.2165/00003495-200464090-00001 · Cited by 213
Self-citationEffect of Mild Acid on Gene Expression in Staphylococcus aureus
Weinrick, B., Dunman, P. M., McAleese, F., Murphy, E., Projan, S. J., Fang, Y., & Novick, R. P. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.24.8407-8423.2004 · Cited by 203
Intracellular pharmacodynamics of antibiotics
Carryn, S., Chanteux, H., Seral, C., Mingeot-Leclercq, M.-P., Van Bambeke, F., & Tulkens, P. M. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00066-7 · Cited by 201 · cited 1×
“Yet, many of these studies yield contradictory results, and we still lack a clear understanding of which parameters are truly critical for the expression of antibiotic activity in the intracellular milieu (11).”
ResultSelf-citationTHE SURVIVAL OF STAPHYLOCOCCI WITHIN HUMAN LEUKOCYTES
Rogers, D. E., & Tompsett, R. (1952) · Journal of Experimental Medicine · doi:10.1084/jem.95.2.209 · Cited by 201
Hébert, A., Sayasith, K., Sénéchal, S., Dubreuil, P., & Lagacé, J. (2000) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2000.tb09402.x · Cited by 184
IntracellularStaphylococcus aureus: A MECHANISM FOR THE INDOLENCE OF OSTEOMYELITIS
Ellington, J. K., Harris, M., Webb, L., Smith, B. P., Smith, T. L., Tan, K., & Hudson, M. (2003) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.85b6.13509 · Cited by 179
Seral, C., Françoise Van Bambeke, A., & Tulkens, P. M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2283-2292.2003 · Cited by 167
Self-citationTulkens, P., & Trouet, A. (1978) · Biochemical Pharmacology · doi:10.1016/0006-2952(78)90370-2 · Cited by 157
Self-citationMempel, M., Schnopp, C., Hojka, M., Fesq, H., Weidinger, S., Schaller, M., Körting, H. C., Ring, J., & Abeck, D. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.04752.x · Cited by 146
Variant subpopulations of Staphylococcus aureus as cause of persistent and recurrent infections.
Proctor, R. A., Balwit, J. M., & Vesga, Ó. (1994) · PubMed · Cited by 137
Brouillette, É., Grondin, G., Shkreta, L., Lacasse, P., & Talbot, B. G. (2003) · Microbial Pathogenesis · doi:10.1016/s0882-4010(03)00112-8 · Cited by 135
Carryn, S., Françoise Van Bambeke, A., Mingeot‐Leclercq, M., & Tulkens, P. M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2095-2103.2002 · Cited by 132
Self-citationAlexander, E., & Hudson, M. C. (2001) · Applied Microbiology and Biotechnology · doi:10.1007/s002530100703 · Cited by 122
Boyce, J. M., Medeiros, A. A., Papa, E. F., et al. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.1.73 · Cited by 106
Michot, J.-M., Seral, C., Françoise Van Bambeke, A., Mingeot‐Leclercq, M., & Tulkens, P. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2429-2437.2005 · Cited by 97
Self-citationINTRACELLULAR SURVIVAL OF STAPHYLOCOCCI
Kapral, F. A., & Shayegani, M. (1959) · The Journal of Experimental Medicine · doi:10.1084/jem.110.1.123 · Cited by 84
Tyteca, D. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5613 · Cited by 75
Intracellular survival of Staphylococcus aureus within cultured enterocytes
Hess, D. J., Henry‐Stanley, M. J., Erickson, E. A., & Wells, C. L. (2003) · Journal of Surgical Research · doi:10.1016/s0022-4804(03)00314-7 · Cited by 64
Ouadrhiri, Y., Scorneaux, B., Sibille, Y., & Tulkens, P. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1242 · Cited by 64
Self-citationLemaire, S., Françoise Van Bambeke, A., Mingeot‐Leclercq, M., & Tulkens, P. M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki094 · Cited by 59
Self-citationBishayi, B., & Sengupta, M. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00549-8 · Cited by 56
Activity of antibiotics againstStaphylococcus aureus within polymorphonuclear neutrophils
Yancey, R. J., Sanchez, M. S., & Ford, C. W. (1991) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01964421 · Cited by 56
Gentamicin binding to serum and plasma proteins
Myers, D. R., DeFehr, J., Bennett, W. M., Porter, G. A., & Olsen, G. D. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978233356 · Cited by 48
Phagolysosomal Alkalinization and Intracellular Killing of Staphylococcus aureus by Amikacin
Maurin, M., & Raoult, D. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.2.330 · Cited by 46
Scorneaux, B., Ouadrhiri, Y., Anzalone, G., & Tulkens, P. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1225 · Cited by 40
Self-citationThe Importance of Penetration of Antimicrobial Agents into Cells
Schwab, J. C., & Mandell, G. L. (1989) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(20)30282-8 · Cited by 37
Oritavancin: a new avenue for resistant Gram-positive bacteria
Mercier, R.-C., & Hrebickova, L. (2005) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.3.3.325 · Cited by 31
Paillard, D., Grellet, J., Dubois, V., Saux, M., & Quentin, C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.288-293.2002 · Cited by 25
Fan, H., Teti, G., Ashton, S., Guyton, K., Tempel, G. E., Halushka, P. V., & Cook, J. A. (2003) · Cytokine · doi:10.1016/s1043-4666(03)00122-4 · Cited by 24
Annexins I and IV inhibit Staphylococcus aureus attachment to human macrophages
Gotoh, M., Takamoto, Y., Kurosaka, K., Masuda, J., Ida‐Eto, M., Satoh, A., Takayama, E., Kojima‐Aikawa, K., Kobayashi, Y., & Matsumoto, I. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.12.004 · Cited by 24
Activity of antibiotics against microorganisms ingested by mononuclear phagocytes
van den Broek, P. J. (1991) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01964422 · Cited by 24
Peck, O. M., Fan, H., Tempel, G. E., Teti, G., Halushka, P. V., & Cook, J. A. (2004) · Shock · doi:10.1097/01.shk.0000111662.09279.59 · Cited by 21
Al‐Nawas, B. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/41.6.655 · Cited by 20
Glew, R. H., & Moellering, R. C. (1979) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.15.1.87 · Cited by 13
van den Broek, P. J., Buys, L. F. M., Mattie, H., et al. (1986) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/17.6.767 · Cited by 6
Eckart, R. E., Hospenthal, D. R., & Fishbain, J. T. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.6.589.35156 · Cited by 3
Cited by
Novel antibody-antibiotic conjugate eliminates intracellular S. aureus
Lehar, S. M., Pillow, T., Xu, M., Staben, L., Kajihara, K. K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W. L., Hiroshi Morisaki, J., et al. (2015) · Nature · doi:10.1038/nature16057 · Cited by 838
The effects of pH on wound healing, biofilms, and antimicrobial efficacy
Percival, S. L., McCarty, S., Hunt, J. A., & Woods, E. J. (2014) · Wound Repair and Regeneration · doi:10.1111/wrr.12125 · Cited by 471
Intracellular Staphylococcus aureus persisters upon antibiotic exposure
Peyrusson, F., Varet, H., Nguyen, T. K., Legendre, R., Sismeiro, O., Coppée, J.-Y., Wolz, C., Tenson, T., & Van Bambeke, F. (2020) · Nature Communications · doi:10.1038/s41467-020-15966-7 · Cited by 392
Self-citationIntracellular staphylococcus aureus: Live-in and let die
Fraunholz, M., & Sinha, B. (2012) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2012.00043 · Cited by 377
Kahl, B. C., Becker, K., & Löffler, B. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-15 · Cited by 325
Metadata
- Authors
- Barcia-Macay, M., Seral, C., Mingeot-Leclercq, M.-P., Tulkens, P. M., & Van Bambeke, F.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-03
- Volume
- 50
- Issue
- 3
- Pages
- 841-851
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2162573988
- Cited by
- 266
- References
- 46
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.